...
search icon
mygn-img

Myriad Genetics Inc, Common Stock

MYGN

NSQ

$14.98

+$0.08

(0.54%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.36B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.20M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.89
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.04 L
$29.3 H
$14.98

About Myriad Genetics Inc, Common Stock

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMYGNSectorS&P500
1-Week Return2.25%0.54%0.54%
1-Month Return19.17%3.28%1.66%
3-Month Return-2.09%3.01%3.83%
6-Month Return-45.8%-4.69%9.77%
1-Year Return-36.26%1.41%23.47%
3-Year Return-41.62%15.72%42.73%
5-Year Return-24.69%42.38%82.01%
10-Year Return-56.35%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue851.10M557.00M690.60M678.40M753.20M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.44,"profit":true},{"date":"2021-12-31","value":81.14,"profit":true},{"date":"2022-12-31","value":79.71,"profit":true},{"date":"2023-12-31","value":88.5,"profit":true}]
Cost of Revenue201.00M178.20M197.60M202.00M236.20M[{"date":"2019-12-31","value":85.1,"profit":true},{"date":"2020-12-31","value":75.44,"profit":true},{"date":"2021-12-31","value":83.66,"profit":true},{"date":"2022-12-31","value":85.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit650.10M378.80M493.00M476.40M517.00M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":58.27,"profit":true},{"date":"2021-12-31","value":75.83,"profit":true},{"date":"2022-12-31","value":73.28,"profit":true},{"date":"2023-12-31","value":79.53,"profit":true}]
Gross Margin76.38%68.01%71.39%70.22%68.64%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.03,"profit":true},{"date":"2021-12-31","value":93.46,"profit":true},{"date":"2022-12-31","value":91.94,"profit":true},{"date":"2023-12-31","value":89.86,"profit":true}]
Operating Expenses641.40M653.30M681.70M600.10M774.40M[{"date":"2019-12-31","value":82.83,"profit":true},{"date":"2020-12-31","value":84.36,"profit":true},{"date":"2021-12-31","value":88.03,"profit":true},{"date":"2022-12-31","value":77.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income7.60M(194.80M)(48.70M)(123.70M)(257.40M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2563.16,"profit":false},{"date":"2021-12-31","value":-640.79,"profit":false},{"date":"2022-12-31","value":-1627.63,"profit":false},{"date":"2023-12-31","value":-3386.84,"profit":false}]
Total Non-Operating Income/Expense(7.70M)-(14.30M)(17.50M)(5.20M)[{"date":"2019-12-31","value":-770000000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1430000000,"profit":false},{"date":"2022-12-31","value":-1750000000,"profit":false},{"date":"2023-12-31","value":-520000000,"profit":false}]
Pre-Tax Income7.70M(283.70M)(57.10M)(140.60M)(262.20M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-3684.42,"profit":false},{"date":"2021-12-31","value":-741.56,"profit":false},{"date":"2022-12-31","value":-1825.97,"profit":false},{"date":"2023-12-31","value":-3405.19,"profit":false}]
Income Taxes(4.40M)59.90M(29.90M)(28.60M)1.10M[{"date":"2019-12-31","value":-7.35,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-49.92,"profit":false},{"date":"2022-12-31","value":-47.75,"profit":false},{"date":"2023-12-31","value":1.84,"profit":true}]
Income After Taxes12.10M-(27.20M)(112.00M)(263.30M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-224.79,"profit":false},{"date":"2022-12-31","value":-925.62,"profit":false},{"date":"2023-12-31","value":-2176.03,"profit":false}]
Income From Continuous Operations(199.60M)-(27.20M)(112.00M)(263.30M)[{"date":"2019-12-31","value":-19960000000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-2720000000,"profit":false},{"date":"2022-12-31","value":-11200000000,"profit":false},{"date":"2023-12-31","value":-26330000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income4.60M(223.70M)(27.20M)(112.00M)(263.30M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-4863.04,"profit":false},{"date":"2021-12-31","value":-591.3,"profit":false},{"date":"2022-12-31","value":-2434.78,"profit":false},{"date":"2023-12-31","value":-5723.91,"profit":false}]
EPS (Diluted)1.18(0.66)0.02(0.30)(0.28)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-55.93,"profit":false},{"date":"2021-12-31","value":1.69,"profit":true},{"date":"2022-12-31","value":-25.42,"profit":false},{"date":"2023-12-31","value":-23.73,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MYGN
Cash Ratio 0.65
Current Ratio 1.90
Quick Ratio 1.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MYGN
ROA (LTM) -5.35%
ROE (LTM) -16.40%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MYGN
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MYGN
Trailing PE NM
Forward PE 158.73
P/S (TTM) 1.65
P/B 1.85
Price/FCF NM
EV/R 1.70
EV/Ebitda NM
PEG 1.40

FAQs

What is Myriad Genetics Inc share price today?

Myriad Genetics Inc (MYGN) share price today is $14.98

Can Indians buy Myriad Genetics Inc shares?

Yes, Indians can buy shares of Myriad Genetics Inc (MYGN) on Vested. To buy Myriad Genetics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MYGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Myriad Genetics Inc be purchased?

Yes, you can purchase fractional shares of Myriad Genetics Inc (MYGN) via the Vested app. You can start investing in Myriad Genetics Inc (MYGN) with a minimum investment of $1.

How to invest in Myriad Genetics Inc shares from India?

You can invest in shares of Myriad Genetics Inc (MYGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in MYGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Myriad Genetics Inc shares
What is Myriad Genetics Inc 52-week high and low stock price?

The 52-week high price of Myriad Genetics Inc (MYGN) is $29.3. The 52-week low price of Myriad Genetics Inc (MYGN) is $12.04.

What is Myriad Genetics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Myriad Genetics Inc (MYGN) is 1.85

What is the Market Cap of Myriad Genetics Inc?

The market capitalization of Myriad Genetics Inc (MYGN) is $1.36B

What is Myriad Genetics Inc’s stock symbol?

The stock symbol (or ticker) of Myriad Genetics Inc is MYGN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top